Physician profile
Christopher Tanner
NPI 1922566728
$1,714.18
in general payments reported to CMS, 2019-2025
23 companies · $564 in 2025
The $564 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $553 · 2022: $597 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.48 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $250.39 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $205.96 | 2025 | Breztri, Airsupra, Farxiga |
| Sunovion Pharmaceuticals INC. | $102.51 | 2021-2022 | |
| Novo Nordisk INC | $88.39 | 2022-2025 | Rybelsus, Ozempic |
| Lundbeck LLC | $85.97 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $83.64 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.21 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $48.41 | 2021 | |
| Lilly USA, LLC | $45.33 | 2021 | |
| Exact Sciences Corporation | $40.23 | 2025 | The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $38.04 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.92 | 2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $35.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.73 | 2022 | |
| Axsome Therapeutics, INC. | $28.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.57 | 2021 | |
| Endo Pharmaceuticals INC. | $21.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.85 | 2025 | Jardiance |
| Eisai INC. | $16.53 | 2021 | |
| Leo Pharma INC. | $15.45 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.